Search results for: Mouse anti human Neuregulin Anti-Human antibodies
#29059433 
//
To Up
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Plasticity of the ERBB receptor network has been suggested to cause acquired resistance to anti-human epidermal growth factor receptor 2 (HER2) therapies. Thus, we studied whether a novel approach using an ERBB1-3-neutralizing antibody mixture can block these compensatory mechanisms of resistance.Luis J Schwarz, Katherine E Hutchinson, Brent N Rexer, Mónica Valeria Estrada, Paula I Gonzalez Ericsson, Melinda E Sanders, Teresa C Dugger, Luigi Formisano, Angel Guerrero-Zotano, Monica Red-Brewer, Christian D Young, Johan Lantto, Mikkel W Pedersen, Michael Kragh, Ivan D Horak, Carlos L Arteaga
1173 related Products with: An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
100 ug100ug Lyophilized100ug Lyophilized100ul4 Membranes/Box100 µg100ug Lyophilized100ug100ug Lyophilized1 Set4 Arrays/Slide100ug Lyophilized
Related Pathways
#11121407 2000/12/19
To Up
Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function.
Epidermal growth factor (EGF) family of growth factors and their receptors regulate normal and cancerous epithelial cell proliferation, a process that can be suppressed by antireceptor blocking antibodies. To identify genes whose expression may be modulated by antireceptor blocking antibodies, we performed a differential display screen with cells grown in the presence or absence of antireceptor blocking antibodies; isolates from one cDNA clone were 100% identical to human heterogeneous nuclear ribonucleoprotein K (hnRNP K), a protein with a conserved KH motif and RGG boxes, has been implicated in such functions as sequence-specific DNA binding, transcription, RNA binding, and nucleocytoplasmic shuttling. Both EGF and heregulin-beta1 induced expression of hnRNP K mRNA and protein in human breast cancer cells. This growth factor-mediated hnRNP K expression was effectively blocked by pretreatment of cultures with humanized anti-EGF receptor (EGFR) antibody C225, or anti-human epidermal growth factor receptor-2 (HER2) antibody. Anti-EGFR monoclonal antibody also caused regression of human tumor xenografts and reduction in hnRNP K levels in athymic mice. Samples from grade III human breast cancer contained more hnRNP K protein than samples from grade II cancer. Finally, overexpression of hnRNP K in breast cancer cells significantly increased target c-myc promoter activity and c-Myc protein, hnRNP K protein levels, and enhanced breast cancer cell proliferation and growth in an anchorage-independent manner. These results suggested that the activity of human EGF receptor family members regulates hnRNP K expression by extracellular growth promoting signals and that therapeutic humanized antibodies against EGFR and HER2 can effectively block this function.M Mandal, R Vadlamudi, D Nguyen, R A Wang, L Costa, R Bagheri-Yarmand, J Mendelsohn, R Kumar